Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai, BMS Enter Global Anticancer ADC Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eisai, BMS Enter Global Anticancer ADC Alliance

BMS to pay as much as $2.45B to co-develop Eisai’s MORAb-202

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
 
MORAb-202 is Eisai’s first ADC and combines Eisai’s in house developed anti-folate receptor alpha (FRalpha) antibody, and anticancer agent eribulin. It’s a potential best-in-class FR alpha ADC with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. Eisai is currently investigating MORAb-202 in FRalpha-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a Phase 1 study in Japan and a Phase 1/2 study in the U.S. The companies plan to move into the registrational stage of development as early as next year.
 
Eisai and BMS will jointly develop and commercialize MORAb-202 in the following collaboration territories: Japan; China; the Asia-Pacific region; the U.S.; Canada; Europe, the UK; and Russia. BMS will be responsible for developing and commercializing the drug in regions outside of the collaboration territories. Eisai will remain responsible for the manufacture and supply of MORAb-202 globally.
 
BMS will pay $650 million, including $200 million, as payment toward Eisai R&D expenses. Eisai is also entitled to receive up to $2.45 billion in potential milestones. The companies will share profits, R&D and commercialization costs in the collaboration territories. Eisai is expected to book sales of MORAb-202 in Japan, China, countries in the Asia-Pacific region, Europe and Russia. BMS is expected to book sales of MORAb-202 in the U.S. and Canada.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics